TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
PR Newswire•28/10/2026•16:30 ET
0
Key Highlights
- ➤TransCode (RNAZ) initiates formal strategic process for company and oncology portfolio
- ➤Tungsten Advisors retained as exclusive strategic financial advisor
- ➤TTX-MC138 advances into Phase 2a for ctDNA-positive colorectal cancer
- ➤Strategic alternatives include licensing, partnerships, asset sales and business combinations
- ➤Phase 1a reported stable disease in 10 of 14 efficacy-evaluable patients
Expert Statements
Philippe P. Calais, CEO and Chairman of TransCode Therapeutics
“TTX-MC138 has advanced into Phase 2a clinical development following our Phase 1a study, which provided initial safety data and reports of stable disease,”
Philippe P. Calais, CEO and Chairman of TransCode Therapeutics
“We believe a formal strategic process will help us evaluate opportunities to support the continued development of TTX-MC138 and our broader oncology portfolio, while seeking to maximize value for our stockholders.”
TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio PR Newswire
Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-intent treatment
Get started
Create a free account to read the full story.